There is a case being litigated that brings the issue of coercively questioning employees about their medications before a court of law. This all started with a blog post by Fr. Matthew Schneider, “If Any Drug Tested on HEK-293 Is Immoral, Goodbye Modern Medicine.” The following is a version of an exhibit prepared in support of plaintiffs’ counsel. A number of readers requested access to this summary, and I have decided to post it, but any specifics associated with the case being litigated cannot be disclosed.

I wish to call attention to a comment made in the preface of the summary, mentioning the real and very serious impacts this whole issue has had on many individuals and families. We hear the stories every day. Lives have been turned upside-down, careers have been ended, jobs have been lost, families have had to deal with inability to pay the rent or the mortgage, educations have been suspended, grandparents have gone isolated. I wonder if the people involved, particularly Fr. Schneider and those who use his list, realize the very real consequences and damage that has been done to people of faith, conscience, and good will. We have fought on behalf of these people, not because we sought after it but because they contact us in panic and despair, and thankfully, we have prevailed almost every time. Like many, I have often questioned the motive of those who resort to coercion to enforce vaccine mandates. It seems evil.

Here is the summary and list I compiled and submitted.


Examination of the Conway Regional Health System/Fr. Matthew Schneider List of Medications: Discovery, Origins and Development

Preface

The origin of this list dates back to a blog post written by Fr. Matthew Schneider in January of 2021.  The post originally appeared on his personal blog, linked to here: “If Any Drug Tested on HEK-293 Is Immoral, Goodbye Modern Medicine.”

The blog post was not immediately notorious, as personal blogs tend to have limited reach and readership. The post was brought to my attention several months later, framed in the context of the broader COVID-19 vaccine debates. Fr. Schneider’s intent was to point out hypocrisy and inconsistency on the part of those that took an absolute position on the question of morality, of the use of aborted fetal cell lines in the foundational research, development, and testing of the three authorized COVID-19 vaccines. A statement of equivalence was made, that a great many prescription and OTC medications in common use were tested using aborted fetal cell lines in the same manner as the three authorized COVID-19 vaccines.

The research and development teams for the individual vaccine candidates all leveraged a common body of work funded by the National Institute of Health and the National Institute of Allergy and Infectious Diseases, that being the foundational research leading to the synthesis of the SARS-CoV-2 S1 and S2 subunit spike proteins.[1] This body of work employed aborted fetal cell lines, specifically FreeStyle 293 (trade name for HEK-293), as an expression medium for the subunit proteins.

Moderna, Johnson & Johnson and Pfizer all referenced this work in the subsequent development of their vaccine candidates.  Beyond that, all three companies used aborted fetal cell lines as expression media for development and testing purposes.[2] This is not disputable as the specific applications are documented in the scientific literature.

A thorough review of the use of aborted fetal cell lines in the research, development and testing of the three authorized (and one approved) vaccine leads one to conclude that these vaccines would not exist but for the use of aborted fetal cell lines.

This establishes the foundation upon which one evaluates the statement of equivalence. I did so in May of 2021 in the following article, posted on the Children of God for Life, Inc., website: “Let’s Get a Few Things Cleared Up: Testing, Cell Lines, and Fetal Tissue.”

The commentary did not originally include a summary of the underlying research. The research summary for the fourteen medications selected from the list was subsequently posted on the Children of God for Life, Inc., website in September of 2021 in response to requests from readership. The summary, combined with additional research, follows these prefacing comments.

The general argument and a good portion of the list of medications presented by Fr. Matthew Schneider was used by Conway Regional Health System, a hospital in Conway, Arkansas, as a means to pressure and further burden employees seeking religious exemptions from vaccine mandates. This approach has since been adopted by many other organizations and one may conclude that the reason for this adoption is the same, to further pressure and burden individuals seeking reasonable accommodation for their sincerely held religious beliefs, claiming relief from mandatory vaccine policies. I offer these observations from an authoritative and credible position, having personally counseled many hundreds of individuals seeking religious exemptions from these mandates and having seen the exact same list used by many organizations, among them federal contractors, government employers at the local/state/federal level and employers in the private sector. This argument and general line of thought has caused a great many people of faith and good will a great deal of stress and upheaval in their lives, at times leading to the loss of careers, the indefinite suspension of education and anguish over how to provide for their families.

In the pages that follow, it is quite clear that the origins of most of the listed medications pre-date the availability of aborted fetal cell lines and cell strains. HEK-293, the most commonly used of the aborted fetal cell lines, was deposited in 1973 and was made available to the medical research community in 1977. It would be impossible for any drug developed before 1977 to satisfy the statement of equivalence presented by Fr. Matthew Schneider and subsequently extended by Conway Regional Health System and other organizations.

That aborted fetal cell lines are liberally used in medical research is absolutely true. Indeed, some of the listed medications have been involved with research and/or testing with aborted fetal cell lines subsequent to their development and being brought to market but many of these applications have been indirect, in that the applications had nothing to do with the integrity and formulation of the drug in question and had no bearing on the drug’s formulation and manufacture. A review of the references cited in Fr. Schneider’s blog post and the following references will reveal this.

I am available to discuss the details associated with the summary materials presented herein and the contact information follows.

Prepared by:
Jose L. Trasancos, Ph.D.
Chief Executive Officer, Chairman
Children of God for life, Inc.
jose@cogforlife.org

References

[1] Wrapp, et al, Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation, Science, 13 Mar 2020, Vol 367, Issue 6483, pp. 1260-1263, link:  Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation.

[2] Individual publications linked here: COVID-19 Guidance.

Research Summary

HEK-293 was first available to researchers in 1977, long after many of these products were developed. Their development could not have depended on the use of HEK-293. Four of the 33 listed medications, all four being vaccines whose development history was already well-known, were developed using aborted fetal cell lines or strains (12.1% of the total number of drugs). Note: Tylenol Cold & Flu is a combination of four medications, two of which are documented elsewhere in this summary.

Hydroxychloroquine was first approved for medical use in the U.S. in 1955.

Ivermectin‘s discovery and development used broad animal trials. Ref: Pesticide Synthesis Through Rational Approaches (acs.org).

Albuterol (Ventolin) was discovered in 1966 and marketed in the UK as Ventolin in 1969. Ref: Landau R (1999). Pharmaceutical innovation: revolutionizing human health. Philadelphia: Chemical Heritage Press. p. 226.; Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 321.

Aspirin was first discovered in 1853. A U.S. patent was awarded to Bayer in 1900. Ref: Aspirin – Wikipedia. The first reference given by Fr. Schneider for aspirin is a paper describing a purely exploratory examination of acetylsalicylic acid’s inhibiting effects on capsaicin and heat induced responses in dorsal root ganglia neurons. Here are the relevant details of the paper: 1) None of the authors had any affiliation to a pharmaceutical manufacturer, nor was the research funded by a pharmaceutical manufacturer. 2) The nature of the research was purely exploratory and had nothing to do with the composition of aspirin as an outcome or focus. The second reference from Fr. Schneider has nothing to do with aspirin. This study focused on identifying potential salicylic acid binding proteins. Over 2,000 potential binding proteins were identified. The problem here is that what one buys in a bottle labeled ‘aspirin’ is acetylsalicylic acid, not salicylic acid. The latter is not aspirin, although it is a salicylate. It is important to note that salicylates are naturally occurring. Salicylic acid is treated with acetic anhydride, turning salicylic acid’s hydroxyl group into an ester group. That, then is aspirin. Salicylic acid and acetylsalicylic acid are not the same, chemically or therapeutically. Last, this research was undertaken by the Boyce Thompson Institute, an independent research lab at Cornell University. The research was not done on behalf of any pharmaceutical manufacturer.

Lidocaine was discovered in 1946 and brought to market in 1948. Ref: Scriabine, Alexander (1999). “Discovery and development of major drugs currently in use.” In Ralph Landau; Basil Achilladelis; Alexander Scriabine (eds.). Pharmaceutical Innovation: Revolutionizing Human Health. Philadelphia: Chemical Heritage Press. p. 211.

Metformin was discovered in 1922 and first marketed in France in 1957. Ref: Fischer J (2010). Analogue-based Drug Discovery II. John Wiley & Sons. p. 49.

Metoprolol was first developed in 1969 and patented in 1970. Ref:  Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 461.

Tums is nothing more than calcium carbonate and sugar. It was developed in 1928 by James Harvey Howe, in the basement of his house and first produced for sale in 1930 by the Lewis Howe Company. Ref: Tums – Wikipedia. The two papers cited by Fr. Schneider have nothing to do with Tums, antacids or any other kind of commercial medication. The subject of both papers is the exploration of nano-structured calcium carbonate and other compounds as part of gene insertion techniques.  What was presented as evidence for Tums was not even remotely related to the claim.

Acetaminophen (paracetamol) has some disagreement as to the date of discovery, but the general consensus is 1877. Ref:  Morse, H.N. (1878). “Ueber eine neue Darstellungsmethode der Acetylamidophenole” [On a new method of preparing acetylamidophenol]. Berichte der deutschen chemischen Gesellschaft (in German). 11 (1): 232–233.

Ibuprofen was discovered in 1961 and first marketed in the UK in 1969. Ref: Halford GM, Lordkipanidzé M, Watson SP (2012). “50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart Adams – PubMed (nih.gov).” Platelets23 (6): 415–422.

Dextromethorphan was patented in 1949 and approved for medical use in 1953. Ref: Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 527.

Pepto Bismol was first sold in 1900 as Bismosal. Renamed Pepto-Bismol in 1919. Ref: Bismuth subsalicylate – Wikipedia.

Maalox was first produced commercially in 1949. Ref: Maalox – Wikipedia.

Pseudoephedrine was discovered 1889, most OTCs with pseudoephedrine content pre-date the advent of fetal cell lines. Ref:  Ladenburg, A.; Oelschlägel, C. (1889). “Ueber das “Pseudo-Ephedrin” [On pseudo-ephedrine]. Berichte der Deutschen Chemischen Gesellschaft (in German).

Ex-Lax and Senokot both have an active ingredient, senna glycoside (Lexicomp Online, Lexi Drugs Online, Hudson, Ohio: Lexi-Comp, Inc.; April 17, 2014). As senna glycoside breaks down in the lower GI, the products of this breakdown are a direct irritant to the lining of colonic wall, thus inducing fluid secretion (Sharkey KA, Wallace JL (2011). “Chapter 46. Treatment of Disorders of Bowel Motility and Water Flux; Anti-Emetics; Agents Used in Biliary and Pancreatic Disease.” In Brunton LL, Chabner BA, Knollmann BC (eds). Goodman & Gilman’s The Pharmacological Basis of TherapeuticsNew York, NY (12th ed). Therapeutic use of senna is centuries-old. Ex-Lax was first produced commercially in 1906, having been ‘invented’ by Max Kiss, his contribution being to combine the active ingredient with chocolate (Building of the Day: 423-443 Atlantic Avenue | Brownstoner). Senokot, with the same active ingredient, was first produced with standardized senna in the mid-20th century (The Story of Senokot Products – Medications – Medical Brand Names).

Motrin is a trade name for ibuprofen.  See ibuprofen, above.

Zostavax: FDA approved in 2006, developed and submitted by Merck & Co (Mitka M (July 2006). “FDA approves shingles vaccine: herpes zoster vaccine targets older adults.” JAMA. 296 (2): 157–8. doi:10.1001/jama.296.2.157. PMID 16835412). MRC.5 fetal cell lines were used in its development and manufacture. Merck & Co. pulled Zostavax from the market in May of 2020 and it is no longer available in the United States.

Benadryl (diphenhydramine) was discovered in 1943 by Dr. George Rieveschl at the University of Cincinnati, approved and licensed by the FDA in 1946. Sneader, Walter, John Wiley & Sons 2005, p.405-406. Ref. See PowerPoint presentation by Adam Nasir and Corrigan Hortan.

Sudafed is a trade name for pseudoephedrine. See pseudoephedrine, above.

Preparation H originated as a sunburn ointment and was acquired by American Home Products, Inc., in 1935.

Enbrel (etanercept) was first developed by Dr. Bruce Beutler, the University of Texas Southwestern Medical Center at Dallas, with the first patent related to etanercept filed in 1989. Development employed HL60 cell lines (adult human myeloid leukemia), CHO cell lines (Chinese Hamster Ovary) and SK MEL-109 cell lines (adult human skin melanoma). No fetal cell lines were used in the research and development processes. Ref: Peppel, Beutler, et al., Journal of Experimental Medicine, 1991 Dec 1; 174(6): 1483–1489.

The first patent application, filed in September of 1989 (application US40324189A) by Dr. Beutler and his research team, was approved in August of 1995.  Immunex Corporation entered into a financial agreement with Dr. Beutler and the Board of Regents of the University of Texas to buy the rights and license the patent to etanercept in September of 1998.  This began what many consider to be the first “Patent Thicket” ever used to extend the earnings potential of a patent drug, involving 47 patents from the first approval in 1995 through 2019.

Immunex filed subsequent patents, one of them coincident with the purchase and licensing from Dr. Beutler, et al. and the UT Board of Regents in which they describe the production process of etanercept (soon to be Enbrel), and this production process made use of the WI-26 fetal cell strain as an expression medium.  Amgen acquired Immunex in 2002, along with all patents and rights associated with Enbrel (etanercept).

Historical note:  Dr. Bruce Beutler was awarded the Nobel Prize for Medicine in 2011 for his discoveries related to etanercept.

MMR Vaccine (Priorix) has long been known to be grown in fetal cell lines. WI-38 and MRC-5 aborted fetal cell lines and the RA27-3 rubella viral strain were employed in the development and production of the Priorix vaccine, which was approved by the FDA and licensed since May 2008.

Acetaminophen (paracetamol) See Tylenol.

Claritin (loratadine) was discovered by Dr. Frank Villani and Dr. Charles Magatti in 1976, working at a Schering AG facility in Italy.  No aborted fetal cell lines were used in the research or development of loratadine. Ref: “Blockbuster Drugs: The Rise and Fall of the Pharmaceutical Industry.”.

Zoloft (sertraline) was discovered by Dr. William Welch in 1977, working in Pfizer’s research labs. Sertraline was developed and tested using in vitro and in vivo rat models. Homogenated rat liver and brain tissue media were used. No aborted fetal cell lines or strains were used in the research and development of sertraline. Ref: Welch, W., Discovery and Pre-Clinical Development of the Serotonin Reuptake Inhibitor Sertraline, Advances in Medicinal Chemistry, Volume 3, pages 113—148, 1995 JAI Press Inc.

Azithromycin was discovered in 1980 in Croatia by a team from Pliva Pharmaceuticals, headed by Slobodan Đokić.  This antibiotic was developed and tested using an array of different bacterial cultures, which is typical for antibiotics.  Azithromycin was synthesized from a series of chemical modifications to erythromycin.  Ref: “The Story of Azithromycin”.

Pfizer negotiated the U.S. patent rights with Pliva Pharmaceuticals. Ref: U.S. Patent Number US4517359A.

Varilrix was developed in 1981, approved and licensed for use in 1984. This vaccine is grown in the WI-38 fetal cell strain.

Havrix was approved and licensed for use in 1985 (manufacturer Glaxo SmithKline). Havrix is a trade name for a Hep-A vaccine with several other trade names from other manufacturers using similar formulations in the market. This specific formulation is grown in MRC-5 aborted fetal cell strains.

Prilosec and Prilosec OTC (omeprazole) is a proton pump inhibitor. This drug’s mechanism of action is external to the cells lining the gastrointestinal tract. This drug, and many that share its mechanism of action, were developed and tested using simulated gastric fluids in vitro. No fetal cell lines or cell strains were used in the drug’s discovery or development. Ref: U.S. Patent US20040248942A1.

Simvastatin (Zocor) is summarized in an excerpt from U.S. Patent US10793884B2: “Lovastatin” (Mevacor) is a fungal polyketide produced by Aspergillus terreus (see, e.g., A. W. Alberts, J. et. al., Proc. Natl. Acad. Sci. U.S.A, 1980, 77, 3957-3961 and A. Endo, J. Antibiot. 1980, 33, 334-336; and J. K. Chan, et. al., J. Am. Chem. Soc. 1983, 105, 3334-3336; Y. Yoshizawa, et. al., J. Am. Chem. Soc. 1994, 116, 2693-2694). Simvastatin was developed using generally similar bacterial fermentation techniques but employed e. Coli strains to produce the polyketides. No aborted fetal cell lines or strains were employed in the research and development of Simvastatin. Ref: U.S. Patent US10793884B2.

Lipitor (atorvastatin) is a synthetic statin compound, first made in 1985. In vitro testing during development employed rat models (homogenated rat livers). No fetal cell lines or strains were employed during research and development. Refs: Roth BD (2002). “The discovery and development of atorvastatin, a potent novel hypolipidemic agent.” Progress in Medicinal Chemistry. 40. pp. 1–22.; U.S. Patent US5686104A.

Tylenol Cold and Flu has the following ingredients: Acetaminophen, dextromethorphan (cough suppressant), phenylephrine (decongestant) and guaifenesin (expectorant). Guaifenesin has been in medical use since 1933, phenylephrine since 1938, and dextromethorphan since 1953. All of the ingredients in this preparation pre-date aborted fetal cell lines and cell strains by decades. Development and testing of the ingredients could not have employed aborted fetal cell lines or strains. Refs: Morris H, Wallach J (2014). “From PCP to MXE: a comprehensive review of the non-medical use of dissociative drugs“, Drug Testing and Analysis. 6 (7–8): 614–32. (dextromethorphan), Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery, John Wiley & Sons. p. 541. (phenylephrine), Riviere JE, Papich MG (2013). Veterinary Pharmacology and Therapeutics, John Wiley & Sons. p. 287 (guaifenesin).